Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluorine-18 PSMA 1007 - ABX advanced biochemical compounds GmbH

Next Previous
X
Search
Drug Profile

Fluorine-18 PSMA 1007 - ABX advanced biochemical compounds GmbH

Alternative Names: [18F]-PSMA-1007; F-18-PSMA-1007

Latest Information Update: 21 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator German Cancer Research Center
  • Developer Advanced Biochemical Compounds (ABX GmbH); Centre for Probe Development and Commercialization; Odense University Hospital; Radboud University; Radboud University Nijmegen Medical Centre
  • Class Amides; Imaging agents; Naphthalenes; Pyridines; Radioisotopes; Radiopharmaceutical diagnostics; Urea compounds
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Glioblastoma

Most Recent Events

  • 08 Jan 2024 Centre for Probe Development and Commercialization completes a phase-III clinical trials in Prostate cancer (Diagnosis) in Canada (Parenteral) (NCT04644822)
  • 31 Dec 2023 Radboud University Medical Center completes a phase I trial in Prostate cancer (Diagnosis) in Netherlands (Parenteral) (EudraCT2020-001387-28, NCT04487847)
  • 08 Nov 2023 ABX advanced biochemical compounds GmbH plans a phase III trial for Prostate Cancer (Newly diagnosed) (IV) in January 2024 (NCT06122584)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top